产品和服务 / 产品类型 / 重组蛋白 / 细胞因子 & 细胞因子受体

Recombinant Mouse IL-27A Protein (RP01898)

  • 验证数据展示
  • 对比数据展示
货号: RP01898
促销价:   ¥780
货    期:现货产品
抗体定制
服务咨询
|
扫码下单
享受积分

详细信息

种属
Mouse
表达宿主
HEK293 cells
Calculated MW
24.26 kDa
Observed MW
25-30 kDa
标签
C-His
纯度
≥ 95 % as determined by SDS-PAGE.
内毒素
< 0.01 EU/μg of the protein by LAL method
制剂
Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4.
描述
Recombinant Mouse IL-27 p28/IL-30 Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Phe29-Ser234) of Human Mouse IL-27 p28/IL-30 (Accession #NP_663611.1) fused with a His at the C-terminus.
储存
Store at -20℃.Store the lyophilized protein at -20℃ to -80 ℃ up to 1 year from the date of receipt.
After reconstitution, the protein solution is stable at -20℃ for 3 months, at 2-8℃ for up to 1 week. (1)未开盖的干粉蛋白在 -20°C至-80°C可保存12个月;复溶之后,蛋白溶液在-20°C及以下可保存3个月,在2-8℃可保存1周;
(2)干粉蛋白复溶浓度建议在0.1-0.5 mg/mL,不能低于0.1mg/mL,长期储存请添加保护剂(如0.1%BSA),并分装保存,避免反复冻融;
(3)液体蛋白的保存温度及效期请参考说明书,如对液体蛋白浓度有要求,请提前咨询销售或者技术支持。
复溶
Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles.收到重组蛋白产品之后请检查蛋白冻干粉末是否贴于瓶底,如果粉末浮起,开盖之前请先低温离心。将蛋白用说明书中指定的缓冲液复溶至0.1-0.5 mg/mL(请注意蛋白复溶浓度不能低于0.1 mg/mL),室温平衡5-10 min保证充分溶解,复溶过程中请不要剧烈涡旋及吹打蛋白溶液。如需长期储存,建议复溶时添加载体蛋白或者稳定剂(如0.1% BSA, 5% HSA, 10% FBS 或者 5% 海藻糖),同时将复溶后的蛋白溶液按照需求进行分装,储存于-20°C至-80°C,随取随用,避免反复冻融。

蛋白复溶计算器

请在蛋白复溶计算器中输入蛋白总质量和所需终浓度,快速计算您需要添加溶液的体积吧!
=
÷

背景信息

Interleukin‑27 p28, also known as IL‑30, is a secreted 28 kDa protein that is considered a member of the IL‑6/IL‑12 interfamily cytokine family. p28/IL‑30 is one of several alpha ‑chain proteins that can associate with various beta ‑chain proteins to form heterodimeric cytokines in these families. The alpha -chains (e.g. IL‑6, IL‑11, Cardiotrophin‑1, CLC/CNTF, LIF, Oncostatin M, IL‑23 p19, IL‑27 p28/IL‑30, IL‑12/IL‑35 p35) have a four‑helix bundle structure, while the beta ‑chains (e.g. EBI‑3, CLF‑1, IL‑12/IL‑23 p40) resemble class 1 cytokine receptors. These cytokines utilize heteromeric cell surface receptors which contain shared as well as ligand‑specific subunits. Divergent biological responses are obtained from the combinatorial association of cytokine subunits and their interaction with various combinations of receptor subunits. Complexity in this system is increased by the generation of soluble receptors and by the competition between proteins for shared subunit pairing . p28/IL‑30 is expressed by macrophages and dendritic cells, and is up‑regulated in these cells by inflammatory stimuli . It was first described as a partner with EBI‑3 in the heterodimeric cytokine IL‑27 . IL‑27 signals through a receptor complex composed of IL‑27 R alpha /WSX-1/TCCR and gp130. This interaction enhances the proinflammatory activation of naïve CD4+ T cells, NK cells, mast cells, and monocytes and the cytotoxic activity of CD8+ T cells. IL‑27 also exhibits anti-inflammatory activity, including the induction of IL‑10 production by naïve and memory T cells, the activation of regulatory T cells (Treg), and the suppression of Th17 cytokine secretion . Alternatively, p28/IL‑30 associates with CLF‑1 to create a cytokine that triggers responses through IL‑27 R alpha, IL‑6 R alpha, and gp130. Like IL‑27, p28‑CLF-1 heterodimers co‑stimulate IFN‑ gamma production by NK cells, and induce IL‑10 secretion by CD4+ T cells. In contrast to IL‑27, however, p28‑CLF-1 is reported to promote the differentiation of Th17 cells . A third mode of p28 action enables it to stimulate cells that express both IL‑6 R alpha and gp130, but lack IL‑27 R alpha. Similar to the IL‑6 system, the presence of IL‑6 R alpha on the cell surface is not even required if p28/IL‑30 associates with a soluble form of IL‑6 R alpha. This combination can trigger trans signaling through gp130, a mechanism that has been demonstrated for complexes of IL‑6 with soluble IL‑6 R alpha . Over‑expression of p28/IL‑30 in vivo interferes with humoral antibody responses and protects from IL‑12 induced liver inflammation .

基因ID
Swiss Prot
别名
IL27 p28; IL-27 p28; IL27;IL-27;IL27A;IL-27A;IL27p28;IL-27p28;IL30;p28; IL-30